PROCEPT BioRoboticsMEX:PRCT 54 Return-on-Tangible-Equity is -35.57% as of Mar. 2026. GuruFocus rates MEX:PRCT with a GF Score™ of 54/100 and a GF Value™ of MXN1,536.19 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 760 Medical Devices & Instruments companies, PROCEPT BioRobotics ranks worse than 75.26% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. PROCEPT BioRobotics's annualized net income for the quarter that ended in Mar. 2026 was MXN-2,282 Mil. PROCEPT BioRobotics's average shareholder tangible equity for the quarter that ended in Mar. 2026 was MXN6,416 Mil. Therefore, PROCEPT BioRobotics's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was -35.57%.
The historical rank and industry rank for PROCEPT BioRobotics's Return-on-Tangible-Equity or its related term are showing as below:
MEX:PRCT'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -148.84 Med: -37.82 Max: -24.94
Current: -27.47
During the past 7 years, PROCEPT BioRobotics's highest Return-on-Tangible-Equity was -24.94%. The lowest was -148.84%. And the median was -37.82%.
MEX:PRCT's Return-on-Tangible-Equity is ranked worse than 75.26% of 760
companies
in the Medical Devices & Instruments industry
Industry Median: 4.115
vs MEX:PRCT: -27.47
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
PROCEPT BioRobotics Return-on-Tangible-Equity Related Terms
PROCEPT BioRobotics Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for PROCEPT BioRobotics's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:PRCT vs ALMR, AHCO, ENOV: Return-on-Tangible-Equity Comparison
For the Medical Devices subindustry, PROCEPT BioRobotics's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PROCEPT BioRobotics Return-on-Tangible-Equity vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, PROCEPT BioRobotics's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where PROCEPT BioRobotics's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of -35.57% mean?
PROCEPT BioRobotics (MEX:PRCT) has a Return-on-Tangible-Equity of -35.57% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on PROCEPT BioRobotics and its competitors. According to the industry distribution chart, PROCEPT BioRobotics ranks #572 out of 760 companies in the Medical Devices & Instruments industry, placing it in the top 75.3%.
Is PROCEPT BioRobotics' Return-on-Tangible-Equity too high?
PROCEPT BioRobotics' current Return-on-Tangible-Equity is -35.57%. Based on the distribution chart, PROCEPT BioRobotics ranks #572 out of 760 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, PROCEPT BioRobotics has a GF Score™ of 54/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does PROCEPT BioRobotics' Return-on-Tangible-Equity compare to ALMR and AHCO?
According to the Medical Devices & Instruments industry distribution chart, PROCEPT BioRobotics ranks #572 out of 760 companies for Return-on-Tangible-Equity. This places PROCEPT BioRobotics in the lower half of its industry. The industry median Return-on-Tangible-Equity is 4.12. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Medical Devices & Instruments company?
The median Return-on-Tangible-Equity among Medical Devices & Instruments companies is 4.12, based on 760 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on PROCEPT BioRobotics and its competitors. For the Medical Devices & Instruments industry, the median Return-on-Tangible-Equity is 4.12 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PROCEPT BioRobotics's current Return-on-Tangible-Equity is -35.57%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PROCEPT BioRobotics stock overvalued right now?
Based on GuruFocus' analysis, PROCEPT BioRobotics (MEX:PRCT) is currently considered Significantly Undervalued. The stock's GF Value™ is MXN1,536.19, compared to a current price of MXN358.45 — trading 76.7% below its estimated fair value. The current Return-on-Tangible-Equity is -35.57%. PROCEPT BioRobotics' overall GF Score™ is 54/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For PROCEPT BioRobotics (MEX:PRCT), the current Return-on-Tangible-Equity is -35.57% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PROCEPT BioRobotics (MEX:PRCT) Overvalued in 2026?
Based on GuruFocus' analysis, PROCEPT BioRobotics stock appears to be undervalued.
The current stock price of MXN358.45 is trading 76.7% below its estimated GF Value™ of MXN1,536.19.
GuruFocus considers PROCEPT BioRobotics to be Significantly Undervalued.
Key valuation signals for MEX:PRCT:
Return-on-Tangible-Equity: -35.57%
GF Value™: MXN1,536.19 vs. price of MXN358.45 (76.7% below fair value)
No single metric tells the full story. See the MEX:PRCT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PROCEPT BioRobotics Corp is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. The company develops, manufactures, and sells the AquaBeam Robotic System and HYDROS Robotic System, image-guided, surgical robotic systems for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. Geographically, the company generates a majority of its revenue from the United States and also has a presence in markets outside the U.S.
54GF Score
Get the complete analysis for MEX:PRCT
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:PRCT has been successfully added to your 
